1 not yet recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Filamon LTD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD) BETA-TT8 ophthalmic gel 3.8% w/v - Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 / Phase 2 | Not yet recruiting | Filamon LTD | 24 | 2026-09-01 | 2026-09-18 |
| Early Phase Study of KESONOTIDE™in Participants With Solid Tumours A novel hGIIA-Vimentin Inhibitor, Dose expansion - Prostate Cancers, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Filamon LTD | 80 | 2025-11-07 | 2026-03-17 |
Breast Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1) · Macular Degeneration (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Skin Neoplasms (1)
Australia (2)